PDE5 Inhibition Via Tadalafil (Cialis) to Enhance Anti-Tumor MUC1 Vaccine Efficacy in Patients With Resectable, and Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma (HNSCC): A Phase I/II Clinical Trial

Trial Profile

PDE5 Inhibition Via Tadalafil (Cialis) to Enhance Anti-Tumor MUC1 Vaccine Efficacy in Patients With Resectable, and Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma (HNSCC): A Phase I/II Clinical Trial

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs Tadalafil (Primary) ; Cancer vaccine MUC-1; Influenza virus vaccine
  • Indications Head and neck cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 Apr 2016 Treatment arms changed from 4 to 5.
    • 08 Apr 2016 Planned primary completion date changed from 1 Dec 2020 to 1 Apr 2021.
    • 08 Apr 2016 Planned number of patients changed from 54 to 104.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top